AbCellera Biologics (ABCL) Non-Current Deferred Tax Liability (2020 - 2025)

AbCellera Biologics' Non-Current Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $9.1 million for Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 9.32% year-over-year to $9.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.1 million (down 9.32% YoY) and the FY2025 annual result came in at $9.1 million, down 9.32% from the prior year.
• Non-Current Deferred Tax Liability was $9.1 million for Q4 2025 at AbCellera Biologics, down from $9.7 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $77.2 million in Q4 2023 and bottomed at $9.1 million in Q4 2025.
• A 5-year average of $27.8 million and a median of $31.7 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability jumped 132.61% — and 2024, when it sank 86.98%.
• AbCellera Biologics' Non-Current Deferred Tax Liability stood at $37.4 million in 2021, then slipped by 11.22% to $33.2 million in 2022, then soared by 132.61% to $77.2 million in 2023, then sank by 86.98% to $10.1 million in 2024, then fell by 9.32% to $9.1 million in 2025.
• Business Quant data shows ABCL's Non-Current Deferred Tax Liability at $9.1 million in Q4 2025, $9.7 million in Q3 2025, and $10.1 million in Q2 2025.